31 October 2019
Visiongain has launched a new pharma report Global Acute Myeloid Leukaemia Market Report: Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib.
The global acute myeloid leukaemia market is estimated to grow at a CAGR of 13% in the first half of the forecast period. In 2018, the chemotherapy segment held 32% share of the global acute myeloid leukaemia market.
The lead analyst of the report commented "The growth of the acute myeloid leukemia market is estimated to be catalysed by opportunities in emerging markets with high potential due to improving healthcare infrastructure, unmet healthcare needs, rise in chronic diseases, and increased awareness.
The healthcare industry in the emerging nations is developing at a significant rate due to rise in demand for better healthcare services, significant investments by government to improve healthcare infrastructure, and an increase in the incidence of acute myeloid leukemia."
Leading companies featured in the report include Bristol-Myers Squibb Company, Celgene, Clavis Pharma ASA, Daiichi Sankyo, Eisai, GSK, Novartis, Roche, Sunesis Pharmaceuticals Teva and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.
11 October 2021
High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.
07 October 2021
Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.
06 October 2021
Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market